Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857557 | 0.81 | — | — | |
| SCHEMBL18557571 | 0.81 | KDM5B (0.33) | — | |
| SCHEMBL23061339 | 0.78 | TAS2R38 (0.68) | TAS2R38ALDH1A1 | |
| Bicarbonate SCHEMBL10653459 | 0.74 | TAS2R38 (0.48) | TAS2R38ALDH1A1HTTHSD17B10PTGS2 | |
| Thioacetamide SCHEMBL8346695 | 0.74 | TAS2R38 (0.62) | TAS2R38ALDH1A1HTTHSD17B10PTGS2 | |
| Oxalic Acid SCHEMBL5458052 | 0.72 | TAS2R38 (0.46) | TAS2R38ALDH1A1HTTHSD17B10PTGS2 | |
| SCHEMBL8658374 | 0.70 | — | — | |
| SCHEMBL29006037 | 0.70 | — | — | |
| Acetic Acid SCHEMBL28266501 | 0.70 | TAS2R38 (0.56) | TAS2R38ALDH1A1HTTHSD17B10PTGS2 | |
| SCHEMBL1715952 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2020-05-07 | — | — | US | disclosed |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | VYOME THERAPEUTICS LIMITED (IN) | 2020-02-25 | — | — | US | disclosed |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME THERAPEUTICS LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| EP-3328856-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | Vyome Biosciences Pvt. Ltd. (IN) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017631-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2017-02-02 | — | — | WO | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | TAS2R38 564/4885ALDH1A1 1302/4885HTT 105/4885 |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | TAS2R38 3236/4885ALDH1A1 4010/4885HTT 4112/4885 |
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | TAS2R38 3236/4885ALDH1A1 4010/4885HTT 4112/4885 |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | CLPP, CFTR, ELANE | TAS2R38 3236/4885ALDH1A1 4010/4885HTT 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.